Amantadine hydrochloride treatment in olivopontocerebellar atrophy: a long-term follow-up study.
The efficacy of amantadine, a dopamine-releasing agent and antagonist of the N-methyl-D-aspartate glutamate receptor, was evaluated in patients with olivopontocerebellar atrophy. By contrast to an untreated control group whose terminal performance deteriorated on 8 of 8 measurements of reaction time and movement time, patients treated with amantadine for a mean duration of over 40 months had improved performances in 1 of 4 reaction time measurements and in 3 of 4 movement time measurements and remained stable on the others. These results demonstrate long-term benefits of amantadine in olivopontocerebellar atrophy-induced deficits of movement initiation and movement completion.
Botez
M I
MI
Centre Hospitalier de l'Université de Montréal - Campus Hôtel-Dieu, Service de Neurologie, Unité de Neurologie du Comportement, Neurobiologie et Neuropsychologie, Montreal, Qué., Canada.
Botez-Marquard
T
T
Elie
R
R
Le Marec
N
N
Pedraza
O L
OL
Lalonde
R
R
D000328:Adult; D000547:Amantadine / Q000494:pharmacology / Q000627:therapeutic use*; D015259:Dopamine Agents / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009068:Movement / Q000187:drug effects; D009849:Olivopontocerebellar Atrophies / Q000188:drug therapy*; D011930:Reaction Time / Q000502:physiology; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors; D013997:Time Factors; D016896:Treatment Outcome
D015259:Dopamine Agents; D016194:Receptors, N-Methyl-D-Aspartate; D000547:Amantadine